Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Orazio Caffo, MD, of the Santa Chiara Hospital, Trento, Italy, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, sharing his thoughts on the most exciting trial and data updates we can expect to see in the prostate cancer arena.
Transcript
In this moment, I think the major information will be about data concerning enzalutamide in the early setting of patients or ARN-509 in this setting of patients.
In this moment, I think the major information will be about data concerning enzalutamide in the early setting of patients or ARN-509 in this setting of patients.
We use necessary cookies to make this site work. Analytics, preference, and marketing cookies are used only if you choose to allow them. You can change your choice at any time. For more information view our Cookie Policy.